163 related articles for article (PubMed ID: 22987364)
1. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers.
Talseth-Palmer BA; Wijnen JT; Brenne IS; Jagmohan-Changur S; Barker D; Ashton KA; Tops CM; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; ; Spigelman A; Møller P; Morreau HM; Van Wezel T; Lubinski J; Vasen HF; Scott RJ
Int J Cancer; 2013 Apr; 132(7):1556-64. PubMed ID: 22987364
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome.
Talseth-Palmer BA; Brenne IS; Ashton KA; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; Spigelman A; Lubinski J; Scott RJ
J Med Genet; 2011 Apr; 48(4):279-84. PubMed ID: 21097774
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome.
Wijnen JT; Brohet RM; van Eijk R; Jagmohan-Changur S; Middeldorp A; Tops CM; van Puijenbroek M; Ausems MG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Verhoef S; Wagner A; Nagengast FM; Kleibeuker JH; Devilee P; Morreau H; Goldgar D; Tomlinson IP; Houlston RS; van Wezel T; Vasen HF
Gastroenterology; 2009 Jan; 136(1):131-7. PubMed ID: 19010329
[TBL] [Abstract][Full Text] [Related]
4. Is the reported modifying effect of 8q23.3 and 11q23.1 on colorectal cancer risk for MLH1 mutation carriers valid?
Win AK; Jenkins MA
Int J Cancer; 2013 Oct; 133(7):1762-3. PubMed ID: 23536426
[No Abstract] [Full Text] [Related]
5. SNP association study in PMS2-associated Lynch syndrome.
Ten Broeke SW; Elsayed FA; Pagan L; Olderode-Berends MJW; Garcia EG; Gille HJP; van Hest LP; Letteboer TGW; van der Kolk LE; Mensenkamp AR; van Os TA; Spruijt L; Redeker BJW; Suerink M; Vos YJ; Wagner A; Wijnen JT; Steyerberg EW; Tops CMJ; van Wezel T; Nielsen M
Fam Cancer; 2018 Oct; 17(4):507-515. PubMed ID: 29147930
[TBL] [Abstract][Full Text] [Related]
6. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome.
Reeves SG; Meldrum C; Groombridge C; Spigelman A; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Cancer Epidemiol; 2012 Apr; 36(2):183-9. PubMed ID: 21974800
[TBL] [Abstract][Full Text] [Related]
7. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility genetic variants associated with early-onset colorectal cancer.
Giráldez MD; López-Dóriga A; Bujanda L; Abulí A; Bessa X; Fernández-Rozadilla C; Muñoz J; Cuatrecasas M; Jover R; Xicola RM; Llor X; Piqué JM; Carracedo A; Ruiz-Ponte C; Cosme A; Enríquez-Navascués JM; Moreno V; Andreu M; Castells A; Balaguer F; Castellví-Bel S;
Carcinogenesis; 2012 Mar; 33(3):613-9. PubMed ID: 22235025
[TBL] [Abstract][Full Text] [Related]
9. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?
Win AK; Hopper JL; Buchanan DD; Young JP; Tenesa A; Dowty JG; Giles GG; Goldblatt J; Winship I; Boussioutas A; Young GP; Parry S; Baron JA; Duggan D; Gallinger S; Newcomb PA; Haile RW; Le Marchand L; Lindor NM; Jenkins MA
Eur J Cancer; 2013 May; 49(7):1578-87. PubMed ID: 23434150
[TBL] [Abstract][Full Text] [Related]
10. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the MLH1 -93G>a promoter polymorphism in modulating susceptibility risk in Malaysian colorectal cancer patients.
Nizam ZM; Abdul Aziz AA; Kaur G; Abu Hassan MR; Mohd Sidek AS; Yeh LY; Mazuwin M; Ankathil R
Asian Pac J Cancer Prev; 2013; 14(2):619-24. PubMed ID: 23621208
[TBL] [Abstract][Full Text] [Related]
12. Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome.
Castillejo A; Guarinos C; Martinez-Canto A; Barbera VM; Egoavil C; Castillejo MI; Perez-Carbonell L; Sanchez-Heras AB; Segura A; Ochoa E; Lazaro R; Ruiz-Ponte C; Bujanda L; Andreu M; Castells A; Carracedo A; Llor X; Clofent J; Alenda C; Paya A; Jover R; Soto JL
BMC Med Genet; 2011 Jan; 12():12. PubMed ID: 21247423
[TBL] [Abstract][Full Text] [Related]
13. TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.
Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; You JF; Wang WC; Hsiung CA; Yeh CC
PLoS One; 2016; 11(12):e0167354. PubMed ID: 27907203
[TBL] [Abstract][Full Text] [Related]
14. IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer.
Reeves SG; Rich D; Meldrum CJ; Colyvas K; Kurzawski G; Suchy J; Lubinski J; Scott RJ
Int J Cancer; 2008 Sep; 123(6):1339-43. PubMed ID: 18623088
[TBL] [Abstract][Full Text] [Related]
15. Reply to Win and Jenkins.
Talseth-Palmer BA; Wijnen JT; Barker D; Vasen HF; Scott RJ
Int J Cancer; 2013 Oct; 133(7):1764. PubMed ID: 23536415
[No Abstract] [Full Text] [Related]
16. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of low penetrance susceptibility loci in a Dutch familial colorectal cancer cohort.
Middeldorp A; Jagmohan-Changur S; van Eijk R; Tops C; Devilee P; Vasen HF; Hes FJ; Houlston R; Tomlinson I; Houwing-Duistermaat JJ; Wijnen JT; Morreau H; van Wezel T
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3062-7. PubMed ID: 19843678
[TBL] [Abstract][Full Text] [Related]
18. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers.
Ghorbanoghli Z; Nieuwenhuis MH; Houwing-Duistermaat JJ; Jagmohan-Changur S; Hes FJ; Tops CM; Wagner A; Aalfs CM; Verhoef S; Gómez García EB; Sijmons RH; Menko FH; Letteboer TG; Hoogerbrugge N; van Wezel T; Vasen HF; Wijnen JT
Fam Cancer; 2016 Oct; 15(4):563-70. PubMed ID: 26880076
[TBL] [Abstract][Full Text] [Related]
20. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
